UNIVERSITAS
GADJAH MADA
BIOINFORMATICS ANALYSIS OF AHNAK2 AND PIK3CA PROTEINS MUTATIONS IN OVARIAN CANCER
Kezia Uenike, Dr.biol.hom. Nastiti Wijayanti, S.Si., M.Si.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

REFERENCES

Ali, A.T., Al-ani, O., Al-ani, F. 2023. Epidemiology and risk factors for ovarian cancer. *Przeglad Menopauzalny*. **22**(2), pp. 93-104. https://doi.org/10.5114/pm.2023.128661

Blum, M., Andreeva, A., Florentino, L.C., Chuguransky, S.R., Grego, T., Hobbs, E., Pinto, B.L., Orr, A., Paysan-Lafosse, T., Ponamareva, I., Salazar, G.A., Bordin, N., Bork, P., Bridge, A., Colwell, L., Gought, J., Haft, D.H., Letunic, I., Llinares-López, F., Marchler-Bauer, A., Meng-Papaxanthos, L., Mi, H., Natale, D.A., Orengo, C.A., Pandurangan, A.P., Piovesan, D., Rivoire, C., Sigrist, C.J.A., Thanki, N., Thibaud-Nissen, F., Thomas, P.D., Tosatto, S.C.E., Wu, C.H., Bateman, A. 2024. InterPro: the protein sequence classification resource in 2025. *Nucleic Acids Research*. **53**(D1), pp. D444-D45. https://doi.org/10.1093/nar/gkae1082

Budiana, I. N. G., Angelina, M. & Pemayun, T. G. A. 2019. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J Turk Ger Gynecol Assoc*. **20**(1), pp. 47-54. https://doi.org/10.4274/jtgga.galenos.2018.2018.0119

Chan, K. & Gordenin, D.A. 2016. Clusters of Multiple Mutations: Incidence and Molecular Mechanisms. *Annual Review of Genetics.* **49**, pp. 243-267. https://doi.org/10.1146/annurev-genet-112414-054714

Cheung, L.W.T., Walkiewicz, K.W., Besong, T.M.D., Guo, H., Hawke, D.H., Arold, S.T., Mills, G.B. 2015. Regulation of the PI3K pathway through a p85α monomer–homodimer equilibrium. *eLife*. **4**(1), article no. e06866 [no pagination]. https://doi.org/10.7554/eLife.06866

Crespo, J.L., Hall, M.N. 2002. Elucidating TOR Signaling and Rapamycin Action: Lessons from *Saccharomyces cerevisiae. Microbiology and Molecular Biology Reviews*. **66**(4), pp. 579-591. https://doi.org/10.1128/MMBR.66.4.579-591.2002

Cui, Y., Liu, X., Wu, Y., Liang, X., Dai, J., Zhang, Z., Guo, R. 2022. Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. *Frontiers in Oncology*. **12**, article no. 798401 [no pagination]. https://doi.org/10.3389/fonc.2022.798401

Davletov, B.A. & Südhof, T.C. 1993. A Single C2 Domain &om Synaptotagmin I Is Sufficient for High Affinity Ca^{2+}/Phospholipid Binding. *The Journal of Biological Chemistry*. **268**(35), pp.26386-26390. https://doi.org/10.1016/s0021-9258(19)74326-9

Esmaeilzadeh, A. A., Azizikhezri, D., Fatahi, Z., Saeidi, H., Fazel, M., Nasirzadeh, F. 2025. Oncogenes as Diagnostic Biomarkers in Breast Cancer: A Review of Molecular Detection and Clinical Utility. *Iranian Journal of Blood & Cancer*. **17**(2), pp. 70-82. https://ijbc.ir/article-1-1748-en.pdf

Genomics England. 2024. The National Genomic Research Library. *Figshare*. .

UNIVERSITAS
GADJAH MADA
BIOINFORMATICS ANALYSIS OF AHNAK2 AND PIK3CA PROTEINS MUTATIONS IN OVARIAN CANCER
Kezia Uenike, Dr.biol.hom. Nastiti Wijayanti, S.Si., M.Si.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

[Accessed 6 March 2026]. https://doi.org/10.6084/m9.figshare.4530893

Groves, M.R. & Barford, D. 1999. Topological characteristics of helical repeat protein. *Current Opinion in Structural Biology*. **9**(3), pp. 383-389. [Accessed 25 Jan. 26]. https://doi.org/10.1016/S0959-440X(99)80052-9

Harding, A.E. & Thomas, P.K. 1980. The clinical features of hereditary motor and sensory neuropathyy types I and II. *Brain* **103**(2), pp. 259-280. https://doi.org/10.1093/brain/103.2.259

Jenkins, M.L., Ranga-Prasad, H., Parson, M.A.H., Harris, N.J., Rathinaswamy, M.K., Burke, J.E. 2023. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus. *Nature Communications*. **14**(1), article no. 181 https://doi.org/10.1038/s41467-023-35789-6

Jumper, J., Evans, R., Pritzel, A., *et al*., 2021. Highly accurate protein structure prediction with AlphaFold. *Nature*. **596**(1), pp. 583-589. https://doi.org/10.1038/s41586-021-03819-2

Karakas, B., Bachman, K.E., Park, B.H. 2006. Mutation of the PIK3CA oncogene in human cancers. *British Journal of Cancer*. **94**(1), pp. 455-459. https://doi.org/10.1038/sj.bjc.6602970

Keraite, I., Alvarez-Garcia, V., Garcia-Murillas, I., Beaney, M., Turner, N.C., Bartos, C., Oikonomidou, O., Kersaudy-Kerhoas, M., Leslie, N.R. 2020. PIK3CA mutation enrichment and quantitation from blood and tissue. *Scientific Reports*. **10**(1), article no. 17082 [no pagination]. https://doi.org/10.1038/s41598-020-74086-w

Lai, P., Tyrer, J.P., Pharoah, P., Gayther, S.A., Jones, M.R., Peng, P. 2025. Characterizing somatic mutations in ovarian cancer germline risk regions. *Communications Biology*. **8**, article no. 676 [no pagination]. https://doi.org/10.1038/s42003-025-08072-1

Lawrence, M.S., Stojanov, P., Polak, P. *et al*. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature*. **499**(1), pp. 214-218. https://doi.org/10.1038/nature12213

Li, R., Zhao, A., Liu, M., Lu, L., Li, B., Zeng, H. 2026. Global epidemiology of ovarian cancer: patterns, trends, and risk factors. *Cancer Biology & Medicine*. Article no. 20250619 [no pagination]. https://doi.org/10.20892/j.issn.2095-3941.2025.0619

Madeira, F., Madhusoodanan, N., Lee, J., Eusebi, A., Niewielska, A., Tivey, A.R.N., Lopez, R., Butcher, S. 2024. The EMBL-EBI Job Dispatcher sequence analysis tools framework in 2024. *Nucleic Acids Research*. **52**(W1), pp. W521-W525. https://doi.org/10.1093/nar/gkae241

Mai, Z., Kongjia, L., Wang, X., Xie, X., Pang, L., Yang, H., Wen, J., Fu, J. 2024. Impaired TGF-β signaling via AHNAK family mutations elicits an esophageal cancer subtype with sensitivities to genotoxic therapy and immunotherapy. *Cancer Immunology, Immunotherapy*. . **73**(11), article no. 225 [no pagination]. https://doi.org/10.1007/s00262-024-03798-z

Mak, T.W. Saunders, M.E., Jett, B.D. 2014. *Primer to the Immune Response*. 2nd

UNIVERSITAS
GADJAH MADA
BIOINFORMATICS ANALYSIS OF AHNAK2 AND PIK3CA PROTEINS MUTATIONS IN OVARIAN CANCER
Kezia Uenike, Dr.biol.hom. Nastiti Wijayanti, S.Si., M.Si.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

ed. Burlington, MA: Elsevier Inc.

Meng, E.C., Goddard, T.D., Pettersen, E.F., Couch, G.S., Pearson, Z.J., Morris, J.H., Ferrin, T.E. 2023. UCSF ChimeraX: Tools for structure building and analysis. *Tools for Protein Science*. **32**(11), article no. E4792 [no pagination]. https://doi.org/10.1002/pro.4792

Miles, B. & Tadi, P. 2023. Genetics, Somatic Mutation. In: *StatPearls [Internet]*. . Florida, USA: StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557896/

Mirzaa, G., Graham, J.M., Keppler-Noreuil, K. 2013. PIK3CA-Related Overgrowth Spectrum. In: Adam, M.P., Bick, S., Mirzaa, G.M., *et al*. Eds. *GeneReviews® [Internet]*. Seattle (WA): University of Washington. https://www.ncbi.nlm.nih.gov/books/NBK153722/

Nakamura, K., Ishikawa, M., Kawano, R., Aimono, E., Mizuno, T., Nohara, S., Tanishima, S., Hayashi, H., Nishihara, H., The Keio PleSSision Group. 2024. Characterizing multi-*PIK3CA* mutations across cancer types: Toward precision oncology. *Cancer Medicine*. **13**(14), article no. e70052 [no pagination]. https://doi.org/10.1002/cam4.70052

Passaro, A., Bakir, M.A., Hamilton, E.G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I.I., Swanton, C., Peters, S. 2024. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. *Cell*. **187**(7), pp. 1617-1635. https://doi.org/10.1016/j.cell.2024.02.041

Pierotti, M.A., Sozzi, G., Croce. CM. 2003. Mechanisms of oncogene activation. In: Kufe, D.W., Pollock, R.E., Weichselbaum, R.R. *et al*. eds. *Holand-Frei Cancer Medicine*. 6th ed. Hamilton (ON): BC Decker. https://www.ncbi.nlm.nih.gov/books/NBK12538/

Pommié, C., Levadoux, S., Sabatier, R., Lefranc, G., Lefranc, M. 2004. IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties. *Journal of Molecular Recognition*. **17**(1), pp. 17-32. https://doi.org/10.1002/jmr.647

Rogers, M.S. & D'Amato, R.J. 2006. The effect of genetic diversity on angiogenesis. *Experimental Cell Research*. **312**(5), pp. 561-574. https://doi.org/10.1016/j.yexcr.2005.10.021

Samaras, P., Schmidt, T., Frejno, M., Gessulat, S., Reinecke, M., Jarzab, A., Zecha, J., Mergner, J., Giansanti, P., Ehrlich, H., Aiche, S., Rank, J., Kienegger, H., Krcmarr, H., Kuster, B., Wilhelm, M. 2020. ProteomicsDB: a multi-omics and multi-organism resource for life science research. *Nucleic Acids Research*. **48**(D1), pp. D1153-D1163. https://doi.org/10.1093/nar/gkz974

Surveillance, Epidemiology, and End Results (SEER) Program. 2025. SEER Cancer Stat Facts: Ovarian Cancer. *National Cancer Institute. Bethesda, MD.* https://seer.cancer.gov/statfacts/html/ovary.html

Shim, Y.J., Cho, J.H. 2025. *PIK3CA*-related overgrowth spectrum: From genetic mechanisms to targeted treatment with alpelisib. *Journal of Genetic Medicine*. **22**, pp. 47-55. https://doi.org/10.5734/JGM.2025.22.2.47

UNIVERSITAS
GADJAH MADA
BIOINFORMATICS ANALYSIS OF AHNAK2 AND PIK3CA PROTEINS MUTATIONS IN OVARIAN CANCER
Kezia Uenike, Dr.biol.hom. Nastiti Wijayanti, S.Si., M.Si.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Shirev, S.A., Papadopoulos, J.S., Schäffer, A.A., Agarwala, R. 2007. Improved BLAST searches using longer words for protein seeding. *Bioinformatics*. **23**(21), pp. 2949-2951. https://doi.org/10.1093/bioinformatics/btm479

Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., Makowska, M. 2025. Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors' Molecular Backgrounds. *Int. J. Mol. Sci*. **26**(10), article no. 4611 [no pagination]. https://doi.org/10.3390/ijms26104611

Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., Stein, T. I., Nudel, R., Lieder, I., Mazor, Y., Kaplan, S., Dahary, D., Warshawsky, D., Guan-Golan, Y., Kohn, A., Rappaport, N., Safran, M. and Lancet, D. 2016. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Curr Protoc Bioinformatics*. **54**(1), pp. 1.30.1-1.30.33. https://doi.org/10.1002/cpbi.5

Tey, S., Shahrizalia, N., Drew, A.P., *et al*. 2019. Linkage analysis and whole exome sequencing reveals *AHNAK2* as a novel genetic cause for autosomal recessive CMT in a Malaysian family. *Neurogenetics*. **20**, pp. 117-127. https://doi.org/10.1007/s10048-019-00576-3

The Uniprot Consortium. 2025. UniProt: the Universal Protein Knowledgebase in 2025. *Nucleic Acid Research*. **53**(D1), pp. D609-D617. https://doi.org/10.1093/nar/gkae1010

Thorpe, L.M., Yuzugullu, H., Zhao, J.J. 2015. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. *Nature Reviews Cancer*. **15**(1), pp. 7-24. https://doi.org/10.1038/nrc3860

Varadi, M., Anyango, A., Deshpande, M., *et al*., 2021. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Research*. **50**(D1), pp. D439-D444. https://doi.org/10.1093/nar/gkab1061

Varadi, M., Bertoni, D., Magana, P., *et al*. 2024. AlphaFold Protein Structure Database in 2024: providing structure coverage for over 214 million protein sequences. *Nucleic Acids Research*. . **52**(D1), pp. D368-D375. [Accessed 15 December 2025]. https://doi.org/10.1093/nar/gkad1011

Wang, M., Li, X., Zhang, J., Yang, Q., Chen, W., Jin, W., Huang, Y, Yang, R, Gao, W. 2017. AHNAK2 is a Novel Prognostic Marker and Oncogenic Protein for Clear Cell Renal Cell Carcinoma. *Theranostics*. **7**(5), pp. 1100-1113. https://doi.org/10.7150/thno.18198

Waterhouse, A.M., Procter, J.B., Martin, D.M.A., Clamp, M., Barton, G.J. 2009. Jalview Version 2 – A multiple sequence alignment editor and analysis workbench. *Bioinformatics*. **25**, pp. 1189-1191. https://dx.doi.org/10.1093/bioinformatics/btp033

Willensdorfer, M., Bürger, R., Nowak, M.A., 2007. Phenotypic Mutation Rates and the Abundance of Abnormal Proteins in Yeast. *PLoS Computational Biology*. **3**(11), article no: e203 [no pagination]. https://doi.org/10.1371/journal.pcbi.0030203

UNIVERSITAS
GADJAH MADA
BIOINFORMATICS ANALYSIS OF AHNAK2 AND PIK3CA PROTEINS MUTATIONS IN OVARIAN CANCER
Kezia Uenike, Dr.biol.hom. Nastiti Wijayanti, S.Si., M.Si.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Wu, L., Lian, W., Zhao, L. 2021. Calcium signaling in cancer progression and therapy. *The FEBS Journal*. **288**(21), pp. 6187-6205. https://doi.org/10.1111/febs.16133

Xia, B., Yanai, I. 2022. Gene expression levels modulate germline mutation rates through the compound effects of transcription-coupled repair and damage. *Human Genetics*.**141**(1), pp. 1211-1222. https://doi.org/10.1007/s00439-021-02355-3

Xie, L., Lu, X., Zhang, D., Xu, L., Yang, M., Jeong, Y., Chang, S., Xu, X. 2025. Predicting Mutation-Induced Relative Protein-Ligand Binding Affinity Changes via Conformational Sampling and Diversity Integration with Subsampled Alphafold2 in Few-Shot Learning. *BioRχiv*. **1**, pp. 1-28. https://doi.org/10.1101/2025.02.09.637298

Xu, W. Li, A., Zhao, Y., Peng, Y. 2025. Decoding the effects of mutation on protein interactions using machine learning. *Biophysics Reviews*. **6**(1), article no: 011307 [no pagination]. https://doi.org/10.1063/5.0249920

Zardab, M., Roberts, R., Hughes, C., Imrali, A., Saad, A., Chelala, C., Grose, R. P., Kocher, H. M. and Barts Pancreas Tissue, B. 2025. AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility. *Scientific Reports*. 15(1), pp. 2934. https://doi.org/10.1038/s41598-025-87337-5

Zardab, M., Stasinos, K., Grose, R.P., Kocher, H.M. 2022. The Obscure Potential of AHNAK2. *Cancers*. **14**(3), article no. 528 [no pagination]. https://doi.org/10.3390/cancers14030528

Zhang, S., Cai, Z., Li, H. 2023. AHNAKs roles in physiology and malignant tumors. *Frontiers in Oncology*. **13**(1), article no: 1258951 [no pagination]. https://doi.org/10.3389/fonc.2023.1258951